# A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

> **NCT02094365** · PHASE2 · COMPLETED · sponsor: **Alios Biopharma Inc.** · enrollment: 62 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** ALS-008176
- **DRUG:** vehicle

## Key facts

- **NCT ID:** NCT02094365
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094365, "A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02094365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*